As described in the pancreatic cancer section, in this phase 2 trial, the ORR for rucaparib in germline BRCA2 (41%) was similar to that in germline PALB2 (50%) and somatic BRCA2 (50%), suggesting a similar benefit with PALB2 mutations, although the limitation was that numbers were low [44]. This evidence concerns the gene PALB2 and pancreatic neoplasm.